Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.

Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall VLJ, Liu C, Bettington ML, Takeda K, Long GV, Scolyer RA, Lan R, Siemers N, Korman A, Teng MWL, Johnston RJ, Dougall WC, Smyth MJ.

Cancer Immunol Res. 2019 Apr;7(4):559-571. doi: 10.1158/2326-6066.CIR-18-0637. Epub 2019 Mar 20.

2.

Comparison of multi-institutional pre-treatment verification for VMAT of nasopharynx with delivery errors.

Pogson EM, Arumugam S, Hansen CR, Currie M, Blake SJ, Roberts N, Carolan M, Vial P, Alharthi T, Holloway L, Thwaites DI.

Phys Med. 2018 Sep;53:25-31. doi: 10.1016/j.ejmp.2018.07.007. Epub 2018 Aug 10.

PMID:
30241751
3.

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Harjunpää H, Blake SJ, Ahern E, Allen S, Liu J, Yan J, Lutzky V, Takeda K, Aguilera AR, Guillerey C, Mittal D, Li XY, Dougall WC, Smyth MJ, Teng MWL.

Oncoimmunology. 2018 Mar 26;7(7):e1445949. doi: 10.1080/2162402X.2018.1445949. eCollection 2018.

4.

Early-Life Antibiotic-Driven Dysbiosis Leads to Dysregulated Vaccine Immune Responses in Mice.

Lynn MA, Tumes DJ, Choo JM, Sribnaia A, Blake SJ, Leong LEX, Young GP, Marshall HS, Wesselingh SL, Rogers GB, Lynn DJ.

Cell Host Microbe. 2018 May 9;23(5):653-660.e5. doi: 10.1016/j.chom.2018.04.009.

5.

A high DQE water-equivalent EPID employing an array of plastic-scintillating fibers for simultaneous imaging and dosimetry in radiotherapy.

Blake SJ, Cheng Z, McNamara A, Lu M, Vial P, Kuncic Z.

Med Phys. 2018 May;45(5):2154-2168. doi: 10.1002/mp.12882. Epub 2018 Apr 15.

PMID:
29577337
6.

A simple model for transit dosimetry based on a water equivalent EPID.

Deshpande S, Blake SJ, Xing A, Metcalfe PE, Holloway LC, Vial P.

Med Phys. 2018 Mar;45(3):1266-1275. doi: 10.1002/mp.12742. Epub 2018 Jan 24.

PMID:
29314080
7.

Multi-institutional comparison of simulated treatment delivery errors in ssIMRT, manually planned VMAT and autoplan-VMAT plans for nasopharyngeal radiotherapy.

Pogson EM, Aruguman S, Hansen CR, Currie M, Oborn BM, Blake SJ, Juresic J, Ochoa C, Yakobi J, Haman A, Trtovac A, Carolan M, Holloway L, Thwaites DI.

Phys Med. 2017 Oct;42:55-66. doi: 10.1016/j.ejmp.2017.08.008. Epub 2017 Sep 4.

PMID:
29173921
8.

Investigating the impact of treatment delivery uncertainties on treatment effectiveness for lung SABR.

Blake SJ, Arumugam S, Holloway L, Vinod S, Ochoa C, Phan P, Hansen CR, Thwaites DI.

Australas Phys Eng Sci Med. 2017 Dec;40(4):823-829. doi: 10.1007/s13246-017-0591-x. Epub 2017 Oct 30.

PMID:
29086179
9.

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ.

Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31.

PMID:
28759001
10.

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.

Ngiow SF, Young A, Blake SJ, Hill GR, Yagita H, Teng MW, Korman AJ, Smyth MJ.

Cancer Res. 2016 Nov 1;76(21):6266-6277. Epub 2016 Sep 9.

11.

Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.

Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ.

Clin Cancer Res. 2016 Nov 1;22(21):5183-5188. Epub 2016 Sep 12. Review.

12.

In silico investigation of factors affecting the MV imaging performance of a novel water-equivalent EPID.

Blake SJ, Cheng Z, Atakaramians S, Meikle S, Lu M, Vial P, Kuncic Z.

Phys Med. 2016 Dec;32(12):1819-1826. doi: 10.1016/j.ejmp.2016.09.019. Epub 2016 Oct 13.

PMID:
27746099
13.

Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease.

Le Texier L, Lineburg KE, Cao B, McDonald-Hyman C, Leveque-El Mouttie L, Nicholls J, Melino M, Nalkurthi BC, Alexander KA, Teal B, Blake SJ, Souza-Fonseca-Guimaraes F, Engwerda CR, Kuns RD, Lane SW, Teng M, Teh C, Gray D, Clouston AD, Nilsson SK, Blazar BR, Hill GR, MacDonald KP.

JCI Insight. 2016 Sep 22;1(15):e86850. doi: 10.1172/jci.insight.86850.

14.

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.

Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, Young A, O'Donnell JS, Allen S, Smyth MJ, Teng MW.

Cancer Discov. 2016 Dec;6(12):1382-1399. Epub 2016 Sep 23.

15.

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.

Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth MJ.

Cancer Cell. 2016 Sep 12;30(3):391-403. doi: 10.1016/j.ccell.2016.06.025.

16.

Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.

Souza-Fonseca-Guimaraes F, Blake SJ, Makkouk A, Chester C, Kohrt HE, Smyth MJ.

Oncoimmunology. 2016 Jun 30;5(7):e1192740. doi: 10.1080/2162402X.2016.1192740. eCollection 2016 Jul.

17.

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.

Liu J, Blake SJ, Harjunpää H, Fairfax KA, Yong MC, Allen S, Kohrt HE, Takeda K, Smyth MJ, Teng MW.

Cancer Res. 2016 Sep 15;76(18):5288-301. doi: 10.1158/0008-5472.CAN-16-0194. Epub 2016 Aug 8.

18.

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.

Blake SJ, Stannard K, Liu J, Allen S, Yong MC, Mittal D, Aguilera AR, Miles JJ, Lutzky VP, de Andrade LF, Martinet L, Colonna M, Takeda K, Kühnel F, Gurlevik E, Bernhardt G, Teng MW, Smyth MJ.

Cancer Discov. 2016 Apr;6(4):446-59. doi: 10.1158/2159-8290.CD-15-0944. Epub 2016 Jan 19.

19.

Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.

Blake SJ, Ching AL, Kenna TJ, Galea R, Large J, Yagita H, Steptoe RJ.

PLoS One. 2015 Mar 5;10(3):e0119483. doi: 10.1371/journal.pone.0119483. eCollection 2015.

20.

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies.

Liu J, Blake SJ, Smyth MJ, Teng MW.

Clin Transl Immunology. 2014 Aug 1;3(8):e22. doi: 10.1038/cti.2014.18. eCollection 2014 Aug. Review.

21.

Role of IL-17 and IL-22 in autoimmunity and cancer.

Blake SJ, Teng MW.

Actas Dermosifiliogr. 2014 Oct;105 Suppl 1:41-50. doi: 10.1016/S0001-7310(14)70017-1. Review.

PMID:
25398491
22.

Optimisation of the imaging and dosimetric characteristics of an electronic portal imaging device employing plastic scintillating fibres using Monte Carlo simulations.

Blake SJ, McNamara AL, Vial P, Holloway L, Kuncic Z.

Phys Med Biol. 2014 Nov 21;59(22):6827-40. doi: 10.1088/0031-9155/59/22/6827. Epub 2014 Oct 21.

PMID:
25332310
23.

In vivo comparison of local versus systemic delivery of immunostimulating siRNA in HPV-driven tumours.

Khairuddin N, Blake SJ, Firdaus F, Steptoe RJ, Behlke MA, Hertzog PJ, McMillan NA.

Immunol Cell Biol. 2014 Feb;92(2):156-63. doi: 10.1038/icb.2013.75. Epub 2013 Nov 12.

PMID:
24217808
24.

Characterization of a novel EPID designed for simultaneous imaging and dose verification in radiotherapy.

Blake SJ, McNamara AL, Deshpande S, Holloway L, Greer PB, Kuncic Z, Vial P.

Med Phys. 2013 Sep;40(9):091902. doi: 10.1118/1.4816657.

PMID:
24007153
25.

Characterization of optical transport effects on EPID dosimetry using Geant4.

Blake SJ, Vial P, Holloway L, Greer PB, McNamara AL, Kuncic Z.

Med Phys. 2013 Apr;40(4):041708. doi: 10.1118/1.4794479.

PMID:
23556878
26.

Flow cytometric analysis of cell division by dilution of CFSE and related dyes.

Lyons AB, Blake SJ, Doherty KV.

Curr Protoc Cytom. 2013;Chapter 9:Unit9.11. doi: 10.1002/0471142956.cy0911s64. Review.

PMID:
23546777
27.

RNA interference for viral infections.

Blake SJ, Bokhari FF, McMillan NA.

Curr Drug Targets. 2012 Oct;13(11):1411-20. Review.

PMID:
22664094
28.

Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A.

Blake SJ, Hughes TP, Lyons AB.

Exp Hematol. 2012 Aug;40(8):612-21.e6. doi: 10.1016/j.exphem.2012.04.003. Epub 2012 Apr 19.

PMID:
22521768
29.

Single arc volumetric modulated arc therapy for complex brain gliomas: is there an advantage as compared to intensity modulated radiotherapy or by adding a partial arc?

Davidson MT, Masucci GL, Follwell M, Blake SJ, Xu W, Moseley DJ, Sanghera P, Wong CS, Perry J, Tsao M, Sahgal A.

Technol Cancer Res Treat. 2012 Jun;11(3):211-20. Epub 2012 Mar 1.

PMID:
22376134
30.

Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer.

Davidson MT, Blake SJ, Batchelar DL, Cheung P, Mah K.

Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1550-8. doi: 10.1016/j.ijrobp.2010.10.024. Epub 2011 May 3.

PMID:
21543164
31.

siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo.

Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, McMillan NA.

Immunol Cell Biol. 2012 Feb;90(2):187-96. doi: 10.1038/icb.2011.19. Epub 2011 Mar 22.

PMID:
21423261
32.

Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro.

Blake SJ, Lyons AB, Hughes TP.

J Cell Mol Med. 2009 Mar;13(3):599-601. doi: 10.1111/j.1582-4934.2009.00500_1.x. No abstract available.

33.

Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.

Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD.

Exp Hematol. 2009 Feb;37(2):256-65. doi: 10.1016/j.exphem.2008.09.013. Epub 2008 Dec 3.

PMID:
19056158
34.

Dasatinib suppresses in vitro natural killer cell cytotoxicity.

Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP.

Blood. 2008 Apr 15;111(8):4415-6. doi: 10.1182/blood-2008-02-138701. No abstract available.

PMID:
18398058
35.

Metals and organochlorines in pelagic cetaceans stranded on the coasts of England and Wales.

Law RJ, Bennett ME, Blake SJ, Allchin CR, Jones BR, Spurrier CJ.

Mar Pollut Bull. 2001 Jun;42(6):522-6. No abstract available.

PMID:
11468930
36.

Applications of the graphical mode in dynamic CT studies of the brain.

Blake SJ, Sprague NE.

Radiography. 1987 Jul-Aug;53(610):181-3. No abstract available.

PMID:
3671705

Supplemental Content

Loading ...
Support Center